|
2024
|
Invention
|
Pharmaceutical compositions of fumaric acid esters.
Pharmaceutical compositions and dosage forms... |
|
|
Invention
|
Pharmaceutical compositions of dimethyl fumarate.
Pharmaceutical compositions and dosage forms o... |
|
|
Invention
|
Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects.
M... |
|
2023
|
Invention
|
Sotalol compositions and uses of the same. The present invention provides oral solutions containi... |
|
|
Invention
|
Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof.
Methods of treating psoriasi... |
|
|
Invention
|
Oral dosage forms having a high loading of a methyl hydrogen fumarate prodrug.
Oral dosage forms... |
|
2022
|
Invention
|
Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and tr... |
|
2021
|
Invention
|
Pharmaceutical compositions of dimethyl fumarate. Pharmaceutical compositions and dosage forms of... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of hypothyroidism |
|
|
Invention
|
Crystalline form of y-aminobutyric acid analog.
A crystalline form of a γ-aminobutyric acid anal... |
|
|
Invention
|
Treatment of multiple sclerosis and psoriasis using prodrugs of methyl hydrogen fumarate.
Improv... |
|
|
Invention
|
Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof.
Improved oral dosage forms o... |
|
2020
|
Invention
|
Gaba analog prodrug sustained release oral dosage forms.
Sustained release oral dosage forms of ... |
|
|
Invention
|
Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof. Improved oral dosage forms of... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of ADHD, narcolepsy and obesity |
|
2018
|
Invention
|
Pharmaceutical compositions of fumaric acid esters. Pharmaceutical compositions and dosage forms ... |
|
|
Invention
|
Acyloxyalkyl carbamate prodrugs, methods of synthesis and use. The disclosures herein relate gene... |
|
2017
|
Invention
|
Crystalline forms of (n, n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of sy... |
|
|
Invention
|
Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of syn... |
|
2016
|
Invention
|
Gaba analog prodrug sustained release oral dosage forms. Sustained release oral dosage forms of a... |
|
|
Invention
|
Oral dosage forms having a high loading of a gabapentin prodrug.
Sustained release oral dosage f... |
|
|
Invention
|
Methods of synthesizing a levodopa ester prodrug. Methods of synthesizing a levodopa ester prodru... |
|
2015
|
G/S
|
Pharmaceutical preparations and substances for the treatment of neurological diseases and disorde... |
|
|
Invention
|
R)-baclofen prodrug, methods of synthesis and methods of use. Crystalline (3R)-4-{[(1S)-2-methyl-... |
|
|
Invention
|
Prodrugs of gaba analogs, compositions and uses thereof. The present invention provides prodrugs ... |
|
2013
|
G/S
|
Pharmaceutical preparations for the treatment of cardiovascular disorders |
|
2012
|
G/S
|
House mark for a full line of pharmaceutical preparations |
|
|
G/S
|
Pharmaceutical preparations for the treatment of neurological disorders |
|
2011
|
G/S
|
Pharmaceutical research and development |
|
|
G/S
|
Pharmaceutical preparations for the treatment of respiratory disorders, cerebrovascular events, a... |
|
2009
|
G/S
|
pharmaceutical preparations and substances for the treatment of neurological diseases and disorders |
|
2005
|
G/S
|
Pharmaceutical preparations for the treatment of human head lice, human body lice and scabies |
|
2001
|
G/S
|
[ BIOCHEMICALS, NAMELY, TRANSPORTER PROTEINS FOR IMPROVING DRUG TRANSPORT AND ABSORPTION AND OPTI... |
|
1992
|
G/S
|
pharmaceutical for the treatment of heart failure |
|
1986
|
G/S
|
ANTIBIOTIC PHARMACEUTICAL PREPARATION |
|
1982
|
G/S
|
Antibiotic Pharmaceutical Preparations |
|
1980
|
G/S
|
Antibiotic Preparation |
|
1979
|
G/S
|
Antibiotic |
|
1977
|
G/S
|
ANTIBIOTIC PRODUCTS |
|
1975
|
G/S
|
ANTIBIOTIC |
